KANGO SUJAY 4

What Happened
Kango Sujay, a director of Dianthus Therapeutics (DNTH), was granted a derivative award covering 6,090 shares on 2026-05-21. The Form 4 reports an acquisition price of $0.00 (derivative), indicating a compensatory award rather than an open-market purchase or sale. The award will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Key Details

• Transaction date: 2026-05-21; Form 4 filed 2026-05-22 (appears timely).
• Instrument: Derivative award reported as 6,090 shares at $0.00 (acquisition code A).
• Vesting: Full vesting on earlier of first anniversary of grant or the 2027 annual meeting, contingent on continued service (per footnote).
• Shares owned after transaction: Not specified in the supplied filing.
• No sale/exercise or cashless sale reported; this is a compensation grant to an insider (not an outright purchase).

Context
This is a compensation-related award to a non-employee or board director and does not represent an open-market purchase or sale. Such grants are common for director compensation and do not by themselves signal buy/sell intent — they vest in the future and only become owned shares (or exercisable rights) if vesting conditions are met.